Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Astellas Pharma Global Development, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity

Phase 3

Recruiting

Conditions: Neurogenic Detrusor Overactivity

Interventions: Drug: mirabegron

First Posted Date: 2022-11-18

Last Posted Date: 2025-06-17

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 10

Registration Number: NCT05621616

Locations: 🇩🇪
Site DE49002, Hannover, Germany
🇹🇷
Site TR90003, Antalya, Turkey
🇺🇸
Stanford Hospital, Palo Alto, California, United States

and more 10 locations

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Phase 3

Completed

Conditions: Geographic Atrophy
Age-Related Macular Degeneration

Interventions: Drug: avacincaptad pegol

First Posted Date: 2022-09-10

Last Posted Date: 2025-07-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 278

Registration Number: NCT05536297

Locations: 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸
Eye Medical Center of Fresno, Fresno, California, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 114 locations

Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis

Completed

Conditions: Chronic Kidney Disease

Interventions: Other: Non-interventional

First Posted Date: 2022-09-07

Last Posted Date: 2024-11-07

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 85259

Registration Number: NCT05530291

Locations: 🇩🇪
Site DE49001, Bad Homburg, Germany

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Gilteritinib
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2022-08-30

Last Posted Date: 2025-06-29

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 70

Registration Number: NCT05520567

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
City of Hope Nat'l Medical Center, Duarte, California, United States
🇺🇸
Univ. of California - Irvine, Irvine, California, United States

and more 17 locations

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Phase 1

Completed

Conditions: Healthy Volunteers
Renal Impairment

Interventions: Drug: pudexacianinium chloride

First Posted Date: 2022-08-10

Last Posted Date: 2024-12-04

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 28

Registration Number: NCT05495581

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States

and more 1 locations

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Completed

Conditions: Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer

First Posted Date: 2022-05-19

Last Posted Date: 2024-11-21

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 1020

Registration Number: NCT05381311

Locations: 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1

Recruiting

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction (GEJ) Adenocarcinoma
Pancreatic Adenocarcinoma

Interventions: Drug: ASP2138
Drug: Pembrolizumab
Drug: Ramucirumab
Drug: Oxaliplatin
Drug: Paclitaxel
Drug: Leucovorin
Drug: Fluorouracil
Drug: Irinotecan

First Posted Date: 2022-05-09

Last Posted Date: 2025-07-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 378

Registration Number: NCT05365581

Locations: 🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇺🇸
UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 39 locations

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 14C-labeled ASP0367

First Posted Date: 2022-02-01

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 9

Registration Number: NCT05217901

Locations: 🇺🇸
Labcorp CRU, Madison, Wisconsin, United States

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: ASP8731 Matching Placebo
Drug: ASP8731

First Posted Date: 2021-12-22

Last Posted Date: 2024-11-20

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 36

Registration Number: NCT05167526

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Phase 1

Completed

Conditions: Renal Impairment
Healthy Volunteers

Interventions: Drug: Bocidelpar

First Posted Date: 2021-11-11

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 13

Registration Number: NCT05117294

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Inland Empire, Rialto, California, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy